BCTX Phase 3 readout: a negative outcome, -7.6%

On January 15, 2026, Interferon infiltration of the inoculation site — BriaCell Therapeutics Corp. (Breast Cancer) reached its Phase 3 readout. The result was a negative outcome, and the stock moved -7.6% in the window around the event. It had already run -12.2% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.